Abstract
Background Estimating the prevalence of rare diseases is challenging due to very limited natural history studies, lack of studies in diverse populations, and frequent under or misdiagnosis. We leveraged human genetics to estimate the genetic prevalence (eGP) of familial Parkinson’s disease (PD) caused by biallelic pathogenic variants in the Parkin (PRKN) gene (PRKN-PD).
Methods We curated the reported PRKN-PD pathogenic variants and obtained the heterozygous carrier frequencies of these variants from gnomAD and the Japanese Multi-omics reference panel (jMorp). We used the carrier frequencies to estimate the eGP of PRKN-PD in eight genetic ancestries.
Results Non-Japanese East Asians presented the highest eGP of PRKN-PD (24 per 100,000 individuals, 95% CI=4-165 per 100,000 individuals), followed by Non-Finnish Europeans (22 in 100,000 individuals, 95% CI = 11-64 per 100,000 individuals). Based on the proportions of races and ethnicities, we estimated the eGP in the USA and the world-wide eGP to be 18 per 100,000 individuals (95% CI=7-68 per 100,000 individuals). and 13 per 100,000 individuals (95% CI=3-70 per 100,000 individuals), respectively. These estimates were significantly reduced when excluding structural variants (world-wide eGP=2 per 100,000 individuals, 95% CI=1-5 per 100,000 individuals).
Conclusions This is the first study estimating the PRKN-PD genetic prevalence. Our results suggest that the prevalence of the disease may be higher than previously reported, highlighting potential underdiagnosis. We also demonstrate the importance of carefully considering the known genetic epidemiology of each disease, and its limitations, when using the approach applied in this study to estimate the disease genetic prevalence.
Competing Interest Statement
DD, CD, JL, SC, TH, JP, DP and GP are employees of Takeda Development Center Americas, Inc.; TH and WQ are employees of Takeda Pharmaceuticals Company Limited. At time of the study, EHMW was an employee of Takeda Development Center Americas, Inc. DD, EHMW, CD, JL, SC, TH, JP, DP and GP are stockholders of Takeda Pharmaceuticals Company Limited. All authors declare no non-financial competing interests.
Funding Statement
Takeda Development Center Americas, Inc. provided funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data. All data sources are listed in the Methods section and include MDSGene (www.mdsgene.org), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), gnomAD (https://gnomad.broadinstitute.org) and JMorp (https://jmorp.megabank.tohoku.ac.jp/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Results section updated to clarify external data used to identify known pathogenic mutations. Revisions do not affect actual results and conclusions.
Data Availability
The study used ONLY openly available human data. All data produced in the present work are contained in the manuscript.
